These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 37291177)

  • 1. Impact of the COVID-19 pandemic on liver transplant waitlist outcome in France.
    Legeai C; Antoine C; Jasseron C; Kerbaul F; Dumortier J
    Sci Rep; 2023 Jun; 13(1):9308. PubMed ID: 37291177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A method for establishing allocation equity among patients with and without hepatocellular carcinoma on a common liver transplant waiting list.
    Vitale A; Volk ML; De Feo TM; Burra P; Frigo AC; Ramirez Morales R; De Carlis L; Belli L; Colledan M; Fagiuoli S; Rossi G; Andorno E; Baccarani U; Regalia E; Vivarelli M; Donataccio M; Cillo U;
    J Hepatol; 2014 Feb; 60(2):290-7. PubMed ID: 24161408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Waitlist mortality and post-liver transplant outcomes of pediatric patients with hepatocellular carcinoma and hepatoblastoma in the United States.
    Wu WK; Ziogas IA; Matsuoka LK; Izzy M; Pai AK; Benedetti DJ; Alexopoulos SP
    Pediatr Blood Cancer; 2022 Jan; 69(1):e29425. PubMed ID: 34736292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lower rates of receiving model for end-stage liver disease exception and longer time to transplant among nonalcoholic steatohepatitis hepatocellular carcinoma.
    Young K; Aguilar M; Gish R; Younossi Z; Saab S; Bhuket T; Liu B; Ahmed A; Wong RJ
    Liver Transpl; 2016 Oct; 22(10):1356-66. PubMed ID: 27348270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MELD EXCEPTION POINTS PROVIDE AN ENOURMOUS ADVANTAGE FOR RECEIVING A LIVER TRANSPLANT IN BRAZIL.
    Arruda S; Chedid MF; Jacinto MM; Álvares-DA-Silva MR
    Arq Gastroenterol; 2020; 57(3):254-261. PubMed ID: 32935744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Impact of Median Model for End-Stage Liver Disease at Transplant Minus 3 National Policy on Waitlist Outcomes in Patients With and Without Hepatocellular Carcinoma.
    Bernards S; Hirose R; Yao FY; Jin C; Dodge JL; Huang CY; Mehta N
    Liver Transpl; 2022 Mar; 28(3):376-385. PubMed ID: 34761847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatic encephalopathy expands the predictivity of model for end-stage liver disease in liver transplant setting: Evidence by means of 2 independent cohorts.
    Lucidi C; Ginanni Corradini S; Abraldes JG; Merli M; Tandon P; Ferri F; Parlati L; Lattanzi B; Poli E; Di Gregorio V; Farcomeni A; Riggio O
    Liver Transpl; 2016 Oct; 22(10):1333-42. PubMed ID: 27434824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validating a novel score based on interaction between ACLF grade and MELD score to predict waitlist mortality.
    Abdallah MA; Kuo YF; Asrani S; Wong RJ; Ahmed A; Kwo P; Terrault N; Kamath PS; Jalan R; Singal AK
    J Hepatol; 2021 Jun; 74(6):1355-1361. PubMed ID: 33326814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel waitlist dropout score for hepatocellular carcinoma - identifying a threshold that predicts worse post-transplant survival.
    Mehta N; Dodge JL; Roberts JP; Yao FY
    J Hepatol; 2021 Apr; 74(4):829-837. PubMed ID: 33188904
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Waiting time predicts survival after liver transplantation for hepatocellular carcinoma: a cohort study using the United Network for Organ Sharing registry.
    Schlansky B; Chen Y; Scott DL; Austin D; Naugler WE
    Liver Transpl; 2014 Sep; 20(9):1045-56. PubMed ID: 24838471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of major hepatocellular carcinoma policy changes on liver transplantation for hepatocellular carcinoma in the United States.
    Shah RH; Chyou D; Goldberg DS
    Liver Transpl; 2022 Dec; 28(12):1857-1864. PubMed ID: 35585774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Natural history of NASH cirrhosis in liver transplant waitlist registrants.
    Lim WH; Ng CH; Tan D; Tseng M; Xiao J; Yong JN; Zeng RW; Cho E; Tay P; Ang CZ; Koh JH; Teng M; Syn N; Kow A; Huang DQ; Tan EX; Rinella ME; Sanyal A; Muthiah M; Siddiqui MS
    J Hepatol; 2023 Oct; 79(4):1015-1024. PubMed ID: 37307997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Excess mortality on the liver transplant waiting list: unintended policy consequences and Model for End-Stage Liver Disease (MELD) inflation.
    Northup PG; Intagliata NM; Shah NL; Pelletier SJ; Berg CL; Argo CK
    Hepatology; 2015 Jan; 61(1):285-91. PubMed ID: 24995689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of the model for end-stage liver disease (MELD) on liver transplantation in one center in Brazil.
    Freitas AC; Itikawa WM; Kurogi AS; Stadnik LG; Parolin MB; Coelho JC
    Arq Gastroenterol; 2010; 47(3):233-7. PubMed ID: 21140081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increasing disparity in waitlist mortality rates with increased model for end-stage liver disease scores for candidates with hepatocellular carcinoma versus candidates without hepatocellular carcinoma.
    Goldberg D; French B; Abt P; Feng S; Cameron AM
    Liver Transpl; 2012 Apr; 18(4):434-43. PubMed ID: 22271656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Delisting HCV-infected liver transplant candidates who improved after viral eradication: Outcome 2 years after delisting.
    Perricone G; Duvoux C; Berenguer M; Cortesi PA; Vinaixa C; Facchetti R; Mazzarelli C; Rockenschaub SR; Martini S; Morelli C; Monico S; Volpes R; Pageaux GP; Fagiuoli S; Belli LS;
    Liver Int; 2018 Dec; 38(12):2170-2177. PubMed ID: 29750389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HEPATOCELLULAR CARCINOMA PATIENTS ARE ADVANTAGED IN THE CURRENT BRAZILIAN LIVER TRANSPLANT ALLOCATION SYSTEM. A COMPETING RISK ANALYSIS.
    Rodríguez S; Fleck AM; Mucenic M; Marroni C; Brandão A
    Arq Gastroenterol; 2020; 57(1):19-23. PubMed ID: 32294731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of Wait-List Mortality Between Cholangiocarcinoma and Hepatocellular Carcinoma Liver Transplant Candidates.
    Ziogas IA; Hickman LA; Matsuoka LK; Izzy M; Montenovo MI; Rega SA; Feurer ID; Alexopoulos SP
    Liver Transpl; 2020 Sep; 26(9):1112-1120. PubMed ID: 32475062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mortality in patients with end-stage liver disease above model for end-stage liver disease 3.0 of 40.
    Kim WR; Mannalithara A; Kwo PY; Bonham CA; Kwong A
    Hepatology; 2023 Mar; 77(3):851-861. PubMed ID: 36052665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of Liver Transplant-Related Survival Benefit in Patients With Versus Without Hepatocellular Carcinoma in the United States.
    Berry K; Ioannou GN
    Gastroenterology; 2015 Sep; 149(3):669-80; quiz e15-6. PubMed ID: 26021233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.